Vienna – June 27, 2007 – onepharm, a young Viennese biotech company specialised in the development of antiviral drugs, has successfully finalised another capital increase with private investors. Together with publicly funded projects and silent partnerships, the company has thus attracted additional funds of more than EUR 2 million since the end of 2006. “With the new capital, we will be able to develop our lead project OPM-3001 in the indication of influenza up to clinical trials and at the same time increase our staff as well as our research and development basis required for this”, says a pleased Dr Bernhard Küenburg, CEO.
